20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Go back to 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
(NASDAQ: AIDX) Delayed: 0.47 --0 (-0%)
Previous Close $0.47    52 Week High
Open $0.47    52 Week Low
Day High $0.47    P/E N/A 
Day Low $0.47    EPS
Volume 20       

(NASDAQ: AIDX) Delayed: 0.47 --0 (-0%)
Previous Close $0.47    52 Week High
Open $0.47    52 Week Low
Day High $0.47    P/E N/A 
Day Low $0.47    EPS
Volume 20